Abu Dhabi, United Arab Emirates : Wellpharma, a subsidiary of Mubadala Bio, has successfully obtained accreditation from the GCC Health Council, a move that strengthens its position as a trusted pharmaceutical manufacturer in the region and supports Mubadala Bio’s efforts to enhance the resilience of the healthcare system and pharmaceutical security regionally .

As a regional company specializing in the manufacture of intravenous solutions and dialysis solutions, Wellpharma continues to support the UAE’s role in building a more integrated healthcare system that relies on local capabilities, ensuring the long-term sustainability of health services in the Middle East and North Africa region and beyond .

This accreditation comes within the framework of the unified regulatory body of the GCC Health Council, following a rigorous evaluation process that included Wilpharma's manufacturing standards, quality management systems, product stability and safety protocols, traceability mechanisms, and operational controls. The evaluation also encompassed the company's capabilities in contamination control, aseptic production, and final sterilization of large and small volumes of injectable liquid formulations, in addition to secondary packaging processes and quality assurance procedures .

Dr. Essam Mohammed, CEO of Mubadala Bio, said : “ This accreditation reflects the strength of our quality systems, manufacturing standards and regulatory practices, which reinforces Wellpharma’s position as a trusted pharmaceutical manufacturer that supports healthcare providers across the region .”

For his part, Hamad Hussein Al Marzouqi, Deputy CEO of Mubadala Bio, affirmed : “This achievement enhances our ability to support pharmaceutical security and expand access to essential medicines in the Gulf markets, in addition to consolidating Abu Dhabi’s position as a regional hub for pharmaceutical industries and pharmaceutical production .”

Accreditation from the GCC Health Council contributes to strengthening cooperation with health and regulatory bodies in the Gulf countries. It also bolsters the confidence of regulators, partners, and healthcare providers in the company's products and manufacturing capabilities. Furthermore, accreditation facilitates product registration procedures, supports export operations, and enhances access to regional procurement programs and healthcare tenders .

As part of Mubadala Bio’s integrated pharmaceutical platform, Abu Dhabi-based Wellpharma is a leading manufacturer of intravenous solutions, dialysis solutions, and a wide range of therapeutic products. The company operates a fully automated facility equipped with state-of-the-art pharmaceutical production technology, adhering to the highest global quality standards. With an annual production capacity of approximately 11 million packages in various forms and sizes, Wellpharma is a key partner in supporting healthcare systems within the UAE and international markets .

-I finish-

#Company Data

About the Bayu Exchange :

Mubadala Bio, a leading pharmaceutical company wholly owned by Mubadala Investment Company, is headquartered in Abu Dhabi and is committed to delivering significant results in the healthcare sectors in the UAE and globally. As a catalyst for progress and innovation, it seeks to accelerate the growth of the pharmaceutical ecosystem by enhancing drug security and ensuring access to essential medicines at competitive prices for all .

Mubadala Bio operates across two strategic pillars: integrated biopharmaceuticals and pharmaceutical logistics, with a core focus on development, production, and enabling local manufacturing to ensure the timely availability of essential medicines and medical devices in high demand. Through its growing footprint across Asia, Africa, and Europe, the company contributes to a sustainable positive impact both locally and internationally .

Mubadala Bio focuses on key biotherapies tailored to global healthcare needs, supporting a comprehensive healthcare system encompassing prevention, treatment, ongoing support, and complementary medicine. Mubadala Bio is committed to fostering innovation, developing national expertise and capabilities, and contributing to the UAE's vision of a knowledge-based economy, ultimately aiming to provide a healthier life for all .

For more information, please visit the website: www.mubadalabio.ae

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.